Resources

Selected
  • Pneumococcal disease
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)

306 results found

2024 ∙ NACI

Recommendations for public health programs on the use of pneumococcal vaccines in children, including the use of 15-valent and 20-valent conjugate vaccines

  • Recommendation
  • Americas
  • Canada
  • Pneumococcal disease
Download:
2023 ∙ Eiden, Amanda L. Barratt, Jane Nyaku, Mawuli K.

A review of factors influencing vaccination policies and programs for older adults globally

  • Adults
  • Older adults
  • Influenza
  • Pneumococcal disease
  • Herpes zoster
  • Tetanus
  • Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2023 ∙ Nagra, D. Bechman, K. Adas, M. Yang, Z. Alveyn, E. Subesinghe, S. Rutherford, A. Allen, V. Patel, S. Russell, M. D. Cope, A. Norton, S. Galloway, J.

A Systematic Review and Meta-Analysis of Anti-Rheumatic Drugs and Pneumococcal Vaccine Immunogenicity in Inflammatory Arthritis

  • All age groups
  • Pneumococcal disease
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Jagne, Isatou von Mollendorf, Claire Wee-Hee, Ashleigh Ortika, Belinda Satzke, Catherine Russell, Fiona M.

A systematic review of pneumococcal conjugate vaccine impact on pneumococcal nasopharyngeal colonisation density in children under 5 years of age

  • Newborn
  • Children
  • Pneumococcal disease
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
2023 ∙ Doggen, Kris van Hoek, Albert Jan Luyten, Jeroen

Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella

  • Newborn
  • Children
  • Adolescents
  • Adults
  • Pneumococcal disease
  • Rotavirus
  • Human papillomavirus (HPV)
  • Meningococcal disease
  • Mumps
  • Measles
  • Rubella
  • Economic aspects
Methodological quality (AMSTAR 2):
Not applicable
2023 ∙ Pichichero, Michael Malley, Richard Kaur, Ravinder Zagursky, Robert Anderson, Porter

Acute otitis media pneumococcal disease burden and nasopharyngeal colonization in children due to serotypes included and not included in current and new pneumococcal conjugate vaccines

  • Children
  • Adolescents
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Scheffer, M. M. J. Coffeng, L. E. O'Mahony, J. F.

Appropriateness of strategy comparisons in cost-effectiveness analyses of infant pneumococcal vaccination: A systematic review

  • Newborn
  • Pneumococcal disease
  • Economic aspects
Methodological quality (AMSTAR 2):
Not applicable
2023 ∙ Du, Yuanze Wang, Yi Zhang, Ting Li, Juanjuan Song, Hewei Wang, Yuanyuan Xu, Yifei Cui, Jingwen Yang, Ming Wang, Zengwu Wu, Xiuyun Wang, Chunping

Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review

  • All age groups
  • Pneumococcal disease
  • Economic aspects
Methodological quality (AMSTAR 2):
Not applicable
2023 ∙ Del Riccio, M. Boccalini, S. Cosma, C. Vaccaro, G. Bonito, B. Zanella, B. Salvati, C. Giorgetti, D. Rigon, L. Biamonte, M. A. Monami, M. Bonanni, P. Bechini, A.

Effectiveness of pneumococcal vaccination on hospitalization and death in the adult and older adult diabetic population: a systematic review

  • Adults
  • Older adults
  • Pneumococcal disease
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
2023 ∙ Wannarong, T. Ekpatanaparnich, P. Boonyasiri, A. Supapueng, O. Vathanophas, V. Tanphaichitr, A. Ungkanont, K.

Efficacy of Pneumococcal Vaccine on Otitis Media: A Systematic Review and Meta-Analysis

  • Newborn
  • Children
  • Pneumococcal disease
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
Loading...